title: Irreversible electroporation of human primary uveal melanoma in enucleated eyes.
abstract: Uveal melanoma (UM) is the most common primary intraocular tumor in adults and is characterized by high rates of metastatic disease. Although brachytherapy is the most common globe-sparing treatment option for small- and medium-sized tumors, the treatment is associated with severe adverse reactions and does not lead to increased survival rates as compared to enucleation. The use of irreversible electroporation (IRE) for tumor ablation has potential advantages in the treatment of tumors in complex organs such as the eye. Following previous theoretical work, herein we evaluate the use of IRE for uveal tumor ablation in human ex vivo eye model. Enucleated eyes of patients with uveal melanoma were treated with short electric pulses (50-100 µs, 1000-2000 V/cm) using a customized electrode design. Tumor bioimpedance was measured before and after treatment and was followed by histopathological evaluation. We found that IRE caused tumor ablation characterized by cell membrane disruption while sparing the non-cellular sclera. Membrane disruption and loss of cellular capacitance were also associated with significant reduction in total tumor impedance and loss of impedance frequency dependence. The effect was more pronounced near the pulsing electrodes and was dependent on time from treatment to fixation. Future studies should further evaluate the potential of IRE as an alternative method of uveal melanoma treatment.
authors.affiliation: Hansen Experimental Physics Laboratory, Stanford University, Stanford, California, United States of America ; Center for Bioengineering in the Service of Humanity and Society, School of Engineering and Computer Science, Hebrew University of Jerusalem, Jerusalem, Israel.
authors.forename: Yossi
authors.initials: Y
authors.lastname: Mandel
authors.forename: Shlomi
authors.initials: S
authors.lastname: Laufer
authors.forename: Michael
authors.initials: M
authors.lastname: Belkin
authors.forename: Boris
authors.initials: B
authors.lastname: Rubinsky
authors.forename: Jacob
authors.initials: J
authors.lastname: Pe'er
authors.forename: Shahar
authors.initials: S
authors.lastname: Frenkel
mesh_terms: D055011:Ablation Techniques; D000368:Aged; D000369:Aged, 80 and over; D018274:Electroporation; D005123:Eye / Q000473:pathology; D015353:Eye Enucleation; D005260:Female; D006801:Humans; D008545:Melanoma / Q000601:surgery*; D008875:Middle Aged; D014604:Uveal Neoplasms / Q000601:surgery*; D000098943:Uveal Melanoma
references.citation: Clin Exp Metastasis. 2008;25(5):509-16
references.pmid: 18335317
references.citation: J Membr Biol. 1999 May 15;169(2):103-9
references.pmid: 10341032
references.citation: Conf Proc IEEE Eng Med Biol Soc. 2006;2006:5056-9
references.pmid: 17946279
references.citation: Phys Med Biol. 2009 Oct 7;54(19):5949-63
references.pmid: 19759406
references.citation: Technol Cancer Res Treat. 2007 Aug;6(4):275-86
references.pmid: 17668934
references.citation: Ophthalmology. 2007 Jul;114(7):1363-71
references.pmid: 17337065
references.citation: Technol Cancer Res Treat. 2007 Feb;6(1):37-48
references.pmid: 17241099
references.citation: Ophthalmology. 2004 Sep;111(9):1768-77
references.pmid: 15350335
references.citation: Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):989-95
references.pmid: 11958893
references.citation: BJU Int. 2011 Jun;107(12):1982-7
references.pmid: 21044244
references.citation: FASEB J. 2003 Aug;17(11):1493-5
references.pmid: 12824299
references.citation: FASEB J. 1999 Feb;13(2):365-76
references.pmid: 9973325
references.citation: IEEE Trans Biomed Eng. 2002 Apr;49(4):400-3
references.pmid: 11942732
references.citation: Acta Ophthalmol (Copenh). 1982 Apr;60(2):161-82
references.pmid: 7136531
references.citation: BMC Cell Biol. 2006 Oct 19;7:37
references.pmid: 17052354
references.citation: Eye (Lond). 2009 Jun;23(6):1254-68
references.pmid: 19265865
references.citation: Retina. 2007 Sep;27(7):908-14
references.pmid: 17891016
references.citation: Br J Ophthalmol. 2008 Aug;92(8):1015-6
references.pmid: 18653591
references.citation: Bioelectrochemistry. 2007 May;70(2):287-95
references.pmid: 17140860
references.citation: Arch Ophthalmol. 2005 Dec;123(12):1639-43
references.pmid: 16344433
references.citation: Arch Ophthalmol. 2006 Dec;124(12):1684-93
references.pmid: 17159027
references.citation: IEEE Trans Biomed Eng. 2006 Jul;53(7):1409-15
references.pmid: 16830945
references.citation: PLoS One. 2007 Nov 07;2(11):e1135
references.pmid: 17989772
references.citation: J Urol. 2008 Dec;180(6):2668-74
references.pmid: 18951581
references.citation: Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8
references.pmid: 11853957
references.citation: Ann Biomed Eng. 2005 Feb;33(2):223-31
references.pmid: 15771276
references.citation: Isr Med Assoc J. 2009 May;11(5):280-5
references.pmid: 19637505
references.citation: Technol Cancer Res Treat. 2005 Dec;4(6):699-705
references.pmid: 16292891
references.citation: Eur J Biochem. 1998 Jun 1;254(2):382-8
references.pmid: 9660195
references.citation: J Natl Cancer Inst. 1976 Mar;56(3):489-91
references.pmid: 1255781
references.citation: Methods Mol Biol. 1998;91:141-7
references.pmid: 9664490
references.citation: Biophys J. 1994 Feb;66(2 Pt 1):524-31
references.pmid: 8161705
references.citation: Am J Pathol. 2006 Oct;169(4):1376-89
references.pmid: 17003493
references.citation: Physiol Meas. 2010 Jul;31(7):995-1009
references.pmid: 20577035
references.citation: Ophthalmology. 2004 May;111(5):977-83
references.pmid: 15121377
references.citation: HPB (Oxford). 2010 Jun;12(5):348-51
references.pmid: 20590911
references.citation: Biophys J. 1998 Sep;75(3):1415-23
references.pmid: 9726943
references.citation: Nat Biotechnol. 1998 Feb;16(2):168-71
references.pmid: 9487524